TW224428B - - Google Patents

Info

Publication number
TW224428B
TW224428B TW080106618A TW80106618A TW224428B TW 224428 B TW224428 B TW 224428B TW 080106618 A TW080106618 A TW 080106618A TW 80106618 A TW80106618 A TW 80106618A TW 224428 B TW224428 B TW 224428B
Authority
TW
Taiwan
Prior art keywords
nonaqueous
pharmaceutical compositions
drug delivery
delivery vehicles
liquid carriers
Prior art date
Application number
TW080106618A
Other languages
English (en)
Chinese (zh)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of TW224428B publication Critical patent/TW224428B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW080106618A 1990-09-27 1991-08-21 TW224428B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/588,697 US5173298A (en) 1990-09-27 1990-09-27 Nonaqueous fluorinated drug delivery vehicle suspensions

Publications (1)

Publication Number Publication Date
TW224428B true TW224428B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1994-06-01

Family

ID=24354930

Family Applications (1)

Application Number Title Priority Date Filing Date
TW080106618A TW224428B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1990-09-27 1991-08-21

Country Status (16)

Country Link
US (1) US5173298A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0550615B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3253072B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100195760B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE125696T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU656919B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2090404C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69111821T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2075468T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE69016B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL99290A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ239558A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT99108B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW224428B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1992005770A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA916770B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048857A (en) * 1989-10-17 2000-04-11 Ellinwood, Jr.; Everett H. Dosing method of administering medicaments via inhalation administration
US5660851A (en) * 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
IE67185B1 (en) * 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
DE69129696T2 (de) * 1990-04-27 1999-02-25 Allergan, Inc., Irvine, Calif. Polymeres arzneimittelabgabesystem
DE4201079C3 (de) * 1992-01-17 1997-09-11 Gramer Eugen Kombinationspräparate zur Augeninnendrucksenkung
AU3924193A (en) * 1992-03-19 1993-10-21 Allergan, Inc. Compositions comprising a drug delivery vehicle suspended in a nonaqueous fluorinated liquid
JP3717925B2 (ja) 1992-09-29 2005-11-16 ネクター セラピューティクス 副甲状腺ホルモンの活性フラグメントの肺導入
US5336487A (en) * 1993-03-05 1994-08-09 Refojo Miguel F Method of treating eye disorders with silicon/fluorosilicone copolymer oil
KR970701739A (ko) 1994-03-04 1997-04-12 브라운 데이비드 피. 블록 공중합체와 그라프트 공중합체 및 이들과 연관된 방법(Block and graft copolymers and methods relating thereto)
DE69532884T2 (de) 1994-03-07 2004-09-02 Nektar Therapeutics, San Carlos Verfahren und mittel zur verabreichung von insulin über die lunge
DE4414755C2 (de) * 1994-04-27 2000-11-16 Lohmann Therapie Syst Lts Kollagenzubereitung zur gesteuerten Abgabe von Wirkstoffen, Verfahren und Verwendung
US5661029A (en) * 1994-05-12 1997-08-26 Biomed Biological culture growth and observation device
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5503869A (en) * 1994-10-21 1996-04-02 Glaxo Wellcome Inc. Process for forming medicament carrier for dry powder inhalator
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
EP0843565A4 (en) * 1995-05-12 2002-10-16 Genentech Inc ADMINISTRATION OF AN AEROSOL CONTAINING COARSE PARTICLES FOR BIOLOGICAL USE
US5667809A (en) * 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874469A (en) * 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
US5861175A (en) 1996-03-15 1999-01-19 Alliance Pharmaceutical Corp. Use of fluorocarbons for diagnosis and treatment of articular disorders
ATE302599T1 (de) * 1996-05-24 2005-09-15 Angiotech Pharm Inc Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
US5955096A (en) * 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US20030077317A1 (en) * 1996-06-25 2003-04-24 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
GB9816724D0 (en) * 1998-08-01 1998-09-30 Boots Co Plc Therapeutic agents
NZ513895A (en) * 1999-02-23 2001-09-28 Univ British Columbia Compositions and methods for improving integrity of compromised body passageways and cavities
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
EP1366758A4 (en) * 2001-02-15 2005-07-20 Sanwa Kagaku Kenkyusho Co NEW OPHTHALMIC COMPOSITIONS
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
AU2004217894B2 (en) 2003-03-03 2010-07-15 Bracco International B.V. Peptides that specifically bind HGF receptor (cMet) and uses thereof
US20050118124A1 (en) * 2003-12-01 2005-06-02 Reinhart Gale M. Compositions for treating keratinous surfaces
WO2005123035A1 (en) * 2004-06-08 2005-12-29 Ocularis Pharma, Inc. Hydrophobic ophthalmic compositions and methods of use
US8153435B1 (en) * 2005-03-30 2012-04-10 Tracer Detection Technology Corp. Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
US20070219127A1 (en) * 2006-03-20 2007-09-20 Walt John G Cyclosporin a compositions
JP2010539245A (ja) 2007-09-14 2010-12-16 日東電工株式会社 薬物担体
US9057712B1 (en) 2011-10-27 2015-06-16 Copilot Ventures Fund Iii Llc Methods of delivery of encapsulated perfluorocarbon taggants
US11904046B1 (en) * 2022-11-14 2024-02-20 Eton Pharmaceuticals, Inc. Hydrocortisone oral liquid formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3911138B1 (en) * 1973-02-26 1996-10-29 Childrens Hosp Medical Center Artificial blood and method for supporting oxygen transport in animals
US4105798A (en) * 1976-07-19 1978-08-08 Sun Ventures, Inc. Perfluoro polycyclic compounds for use as synthetic blood and perfusion media
US4115544A (en) * 1976-08-18 1978-09-19 Alza Corporation Ocular system made of bioerodible esters having linear ether
EP0031353B1 (en) * 1979-06-25 1984-08-08 Suntech, Inc. Use of perfluorocarbon as burn treatment
US4452818A (en) * 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
GR78151B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1982-04-05 1984-09-26 Alcon Lab Inc
US4649047A (en) * 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US4879304A (en) * 1987-05-01 1989-11-07 Angelini Pharmaceuticals Ltd. Ophthalmic compositions and process for preparing
US4882150A (en) * 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
FR2643572A1 (fr) * 1988-12-22 1990-08-31 Rhone Poulenc Chimie Procede d'encapsulation de particules par pelliculage au moyen d'un copolymere silicone thermoplastique

Also Published As

Publication number Publication date
IE69016B1 (en) 1996-07-24
IL99290A0 (en) 1992-07-15
AU8644291A (en) 1992-04-28
DE69111821D1 (de) 1995-09-07
PT99108A (pt) 1993-11-30
NZ239558A (en) 1993-10-26
CA2090404C (en) 2001-11-20
DE69111821T2 (de) 1995-12-14
CA2090404A1 (en) 1992-03-28
WO1992005770A1 (en) 1992-04-16
AU656919B2 (en) 1995-02-23
ATE125696T1 (de) 1995-08-15
PT99108B (pt) 1999-02-26
US5173298A (en) 1992-12-22
EP0550615B1 (en) 1995-08-02
KR100195760B1 (ko) 1999-06-15
ES2075468T3 (es) 1995-10-01
JP3253072B2 (ja) 2002-02-04
JPH06501258A (ja) 1994-02-10
IE913379A1 (en) 1992-04-08
ZA916770B (en) 1992-04-29
IL99290A (en) 1996-09-12
EP0550615A1 (en) 1993-07-14

Similar Documents

Publication Publication Date Title
TW224428B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI902583A7 (fi) Suonensisäinen lääkkeenanto- ja laajennuskatetri
EP2186902A3 (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
DE59009462D1 (de) Implantierbare Vorrichtung zur dosierten Abgabe von Medikamenten in den menschlichen Körper.
EP0217206A3 (en) Medicament against chronic graft-versus-host diseases, as well as against autoimmune diseases, particularly systemic lupus erythematodes
DK0502092T3 (da) Oralt præparat til behandling af inflammatoriske tarmsygdomme
DE3764253D1 (de) Medizinischer saugkoerper mit roentgenkontrastmittel und verfahren zu seiner herstellung.
ITRM910922A1 (it) Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e suo impiego terapeutico
NO20016304L (no) Erytropoetinkonjugater med polyetylenglykol, fremstilling av slike konjugater, preparater omfattende slike konjugater samt anvendelse av slike konjugater for fremstilling av medikamenter for forebygging eller behandling av sykdom
GR3007202T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE59101182D1 (de) Körpergewebeverträgliches Glas.
CA2091134A1 (en) Therapeutic agent for threatened abortion
MY110074A (en) Pharmacuetical formulation.
PT711163E (pt) Utilizacao de benzidamina no tratamento de estados patologicos provocados por tnf
FR2572932B1 (fr) Medicament insoluble administre localement dans l'oreille
NO20001895L (no) Anvendelse av glykosaminoglykaner for fremstilling av farmasøytiske preparater for behandling av diabetes assosierte- øyesykdommer
WO1999003509A3 (de) Pharmazeutische mittel enthaltend perfluoralkylgruppenhaltige trijodaromaten und ihre verwendung in der tumortherapie und interventionellen radiologie
Shved et al. Emoxipine correction of lipid peroxidation disorders in patients with osteoarthrosis deformans
IT8609534A0 (it) Preparato,in particolare collirio o pomata,per il trattamento di alterazioni distrofiche e vascolari dei tessuti oculari.
ES1022564Y (es) Armonizador electromagnetico de las alteraciones fisiologicas del cuerpo humano.
MX9101255A (es) Mejoras en dispositivos desechables para la administracion de soluciones,sangre o plasma
IT1245628B (it) Impiego del viminolo per la preparazione di composizioni farmaceutiche per il trattamento delle tossicodipendenze
ITRM940505A0 (it) "agente attivo per il trattamento di infezioni croniche da immunodepressione e per contrastare lo sviluppo di tumori favoriti da immunodepressione".
ITBO20010506A0 (it) Dispositivo impiantabile per l'elettrostimolazione del ventricolo destro nei pazienti con ritardi o blocchi di conduzione in tale ventricolo
IT1241993B (it) Uso di alfa-chetoglurato di arginina e/oppure di diarginina nella preparazione di composizioni farmaceutiche per il trattamento di deficit psicologici, immunologici e dell'apprendimento